Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Qualigen Therapeutics, Inc. (QLGN) had Return on Tangible Equity of 102.01% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.69M |
|
-- |
|
-- |
|
$1.68M |
|
$-1.68M |
|
$-0.00M |
|
$-1.69M |
|
$-1.69M |
|
$-1.69M |
|
$-1.69M |
|
$-1.69M |
|
$-1.69M |
|
$-1.68M |
|
$-1.58M |
|
1.68M |
|
1.68M |
|
$-1.00 |
|
$-1.00 |
|
| Balance Sheet Financials | |
$3.96M |
|
-- |
|
$0.00M |
|
$3.96M |
|
$5.62M |
|
-- |
|
-- |
|
$5.62M |
|
$-4.44M |
|
$-1.65M |
|
$-1.65M |
|
1.64M |
|
| Cash Flow Statement Financials | |
$-2.69M |
|
$-1.52M |
|
$3.36M |
|
$1.17M |
|
$0.33M |
|
$-0.84M |
|
$0.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.71 |
|
-- |
|
-- |
|
-- |
|
-2.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
37.94% |
|
|
Return on Tangible Equity |
102.01% |
-42.53% |
|
102.01% |
|
$-1.01 |
|
$-1.60 |
|
$-1.60 |
|